Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acer Therapeutics Inc (ACER)

Acer Therapeutics Inc (ACER)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,634
  • Shares Outstanding, K 14,310
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,890 K
  • 60-Month Beta 1.52
  • Price/Sales 8.40
  • Price/Cash Flow N/A
  • Price/Book 4.91
Trade ACER with:

Options Overview Details

View History
  • Implied Volatility 98.14%
  • Historical Volatility 34.08%
  • IV Percentile 10%
  • IV Rank 7.20%
  • IV High 619.68% on 10/26/20
  • IV Low 57.70% on 11/06/20
  • Put/Call Vol Ratio 0.25
  • Today's Volume 15
  • Volume Avg (30-Day) 23
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 499
  • Open Int (30-Day) 255

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.27
  • Low Estimate -0.28
  • Prior Year -0.51
  • Growth Rate Est. (year over year) +45.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.41 +6.14%
on 09/20/21
2.79 -8.24%
on 09/02/21
unch (unch)
since 08/24/21
3-Month
2.28 +12.28%
on 07/20/21
3.10 -17.42%
on 07/29/21
-0.38 (-12.93%)
since 06/24/21
52-Week
2.28 +12.28%
on 07/20/21
5.39 -52.50%
on 03/15/21
+0.18 (+7.56%)
since 09/24/20

Most Recent Stories

More News
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Acer Therapeutics Inc. common stock - ACER

The Rosen Law Firm, P.A. announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit...

ACER : 2.56 (-0.97%)
Opexa Therapeutics, Inc. (ACER) Reports Q2 Loss, Misses Revenue Estimates

Opexa Therapeutics, Inc. (ACER) delivered earnings and revenue surprises of 36.11% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

ACER : 2.56 (-0.97%)
RELIEF THERAPEUTICS Holdings AG: Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders

NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / August 9, 2021 / Acer Therapeutics Inc. (NASDAQ:ACER) (" Acer "), a pharmaceutical company focused on the acquisition, development and commercialization...

ACER : 2.56 (-0.97%)
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

an investor conference themed around investor education and advocacy begins next week, July 13 - 15, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period...

ACOG.VN : 1.350 (-3.57%)
ACER : 2.56 (-0.97%)
ADXN : 9.70 (+1.31%)
AGRX : 1.0300 (unch)
ATGN : 2.0500 (-2.38%)
ABIO : 2.98 (-1.32%)
AUUD : 2.43 (-2.41%)
BASA : 0.3050 (-4.09%)
BMRA : 5.13 (+10.80%)
BKTI : 2.91 (+0.34%)
BSFC : 6.3000 (-1.56%)
DTST : 4.58 (-2.35%)
DCTH : 9.85 (+1.13%)
DMIFF : 0.2478 (+3.25%)
DLPN : 11.54 (-4.63%)
FLUX : 5.70 (-2.81%)
GBNH : 7.47 (-0.40%)
HAVLF : 0.2389 (-3.28%)
ISDR : 25.65 (-4.68%)
INLB : 1.6900 (+5.63%)
KNWN : 2.6375 (-1.95%)
LXXGF : 0.3200 (-2.26%)
MKTY : 8.18 (-2.62%)
MMATF : 13.6500 (-2.15%)
MRVFF : 1.0900 (unch)
NEPH : 9.10 (+4.24%)
NMTC : 4.18 (-1.18%)
NLSP : 2.59 (+1.97%)
OBLG : 2.20 (-1.79%)
PBLA : 2.19 (-4.37%)
POSAF : 0.9800 (-2.00%)
PCSA : 7.90 (+1.41%)
PTIX : 2.07 (+4.55%)
QOEG : 0.0999 (+41.50%)
QIPT : 5.90 (-1.17%)
SNGX : 1.0250 (-1.44%)
STRR : 2.57 (+0.78%)
TGCB : 0.7500 (unch)
VERB : 1.7900 (-3.76%)
WTEQ.CN : 0.105 (-4.55%)
WINT : 1.8900 (-0.53%)
AYRO : 3.60 (-1.10%)
BCTX : 9.19 (+10.99%)
BTX : 9.48 (-5.58%)
HWAL : 1.7520 (unch)
NMRD : 6.10 (+1.84%)
THBRF : 3.9500 (+2.60%)
TRIQ : 0.9399 (-1.06%)
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study

Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.

CANF : 1.6770 (+1.02%)
XNCR : 33.88 (-1.45%)
SVRA : 1.3000 (-2.26%)
ACER : 2.56 (-0.97%)
Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug Rylaze

Jazz Pharma (JAZZ) gets FDA approval for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.

JAZZ : 135.35 (+0.63%)
CANF : 1.6770 (+1.02%)
XNCR : 33.88 (-1.45%)
ACER : 2.56 (-0.97%)
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified...

ACOG.VN : 1.350 (-3.57%)
ACER : 2.56 (-0.97%)
ADXN : 9.70 (+1.31%)
AGRX : 1.0300 (unch)
ATGN : 2.0500 (-2.38%)
ABIO : 2.98 (-1.32%)
AUUD : 2.43 (-2.41%)
BASA : 0.3050 (-4.09%)
BKTI : 2.91 (+0.34%)
BSFC : 6.3000 (-1.56%)
DTST : 4.58 (-2.35%)
DCTH : 9.85 (+1.13%)
DMIFF : 0.2478 (+3.25%)
DLPN : 11.54 (-4.63%)
FLUX : 5.70 (-2.81%)
GBNH : 7.47 (-0.40%)
HAVLF : 0.2389 (-3.28%)
ISDR : 25.65 (-4.68%)
INLB : 1.6900 (+5.63%)
KNWN : 2.6375 (-1.95%)
LXXGF : 0.3200 (-2.26%)
MKTY : 8.18 (-2.62%)
MMATF : 13.6500 (-2.15%)
MRVFF : 1.0900 (unch)
NEPH : 9.10 (+4.24%)
NMTC : 4.18 (-1.18%)
NLSP : 2.59 (+1.97%)
OBLG : 2.20 (-1.79%)
PBLA : 2.19 (-4.37%)
POSAF : 0.9800 (-2.00%)
PCSA : 7.90 (+1.41%)
PTIX : 2.07 (+4.55%)
QOEG : 0.0999 (+41.50%)
QIPT : 5.90 (-1.17%)
SNGX : 1.0250 (-1.44%)
STRR : 2.57 (+0.78%)
TGCB : 0.7500 (unch)
VERB : 1.7900 (-3.76%)
WTEQ.CN : 0.105 (-4.55%)
WINT : 1.8900 (-0.53%)
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics

CPIX : 2.75 (+1.10%)
XNCR : 33.88 (-1.45%)
ACER : 2.56 (-0.97%)
ORGO : 15.42 (-1.22%)
What Makes Opexa Therapeutics, Inc. (ACER) a New Buy Stock

Opexa Therapeutics, Inc. (ACER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ACER : 2.56 (-0.97%)
Thinking about buying stock in Acer Therapeutics, Cemtrex, Comstock Mining, Marker Therapeutics, or Strongbridge Biopharma?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACER, CETX, LODE, MRKR, and SBBP.

LODE : 2.84 (-3.07%)
MRKR : 1.7800 (unch)
SBBP : 2.09 (-1.88%)
ACER : 2.56 (-0.97%)
CETX : 1.1900 (+0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company's product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics,...

See More

Key Turning Points

3rd Resistance Point 2.64
2nd Resistance Point 2.62
1st Resistance Point 2.59
Last Price 2.56
1st Support Level 2.54
2nd Support Level 2.52
3rd Support Level 2.49

See More

52-Week High 5.39
Fibonacci 61.8% 4.20
Fibonacci 50% 3.84
Fibonacci 38.2% 3.47
Last Price 2.56
52-Week Low 2.28

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar